These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 10355069

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
    Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, Trappe HJ, Treese N.
    Z Kardiol; 1999 Mar; 88(3):195-207. PubMed ID: 10355070
    [Abstract] [Full Text] [Related]

  • 3. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial.
    Patten M, Maas R, Bauer P, Lüderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Müller HW, Meinertz T, SOPAT Investigators.
    Eur Heart J; 2004 Aug; 25(16):1395-404. PubMed ID: 15321697
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
    Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, Chang-Sing P, Singh BN.
    Am J Cardiol; 1999 Aug 01; 84(3):270-7. PubMed ID: 10496434
    [Abstract] [Full Text] [Related]

  • 7. [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison].
    Kalusche D, Stockinger J, Betz P, Roskamm H.
    Z Kardiol; 1994 Aug 01; 83 Suppl 5():109-16. PubMed ID: 7846939
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH, van de Loo A, Baedeker F.
    J Am Coll Cardiol; 1995 Oct 01; 26(4):852-8. PubMed ID: 7560608
    [Abstract] [Full Text] [Related]

  • 9. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial.
    Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T.
    J Cardiovasc Electrophysiol; 2006 Nov 01; 17(11):1216-20. PubMed ID: 16987384
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
    Joseph AP, Ward MR.
    Ann Emerg Med; 2000 Jul 01; 36(1):1-9. PubMed ID: 10874228
    [Abstract] [Full Text] [Related]

  • 11. [The effectiveness and safety of d,l-sotalol in the ambulatory treatment of atrial fibrillation and flutter].
    Cruz Cruz F, Iturralde Torres P, Picos Bovio E, Medeiros Domingo A, Infante Vázquez O.
    Arch Inst Cardiol Mex; 1998 Jul 01; 68(6):482-91. PubMed ID: 10365224
    [Abstract] [Full Text] [Related]

  • 12. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
    Naccarelli GV, Dorian P, Hohnloser SH, Coumel P.
    Am J Cardiol; 1996 Jan 25; 77(3):53A-59A. PubMed ID: 8607392
    [Abstract] [Full Text] [Related]

  • 13. [Drug prevention of recurrence in paroxysmal and chronic atrial fibrillation].
    Hindricks G, Kottkamp H, Willems S, Haverkamp W, Borggrefe M, Breithardt G.
    Z Kardiol; 1994 Jan 25; 83 Suppl 5():87-96. PubMed ID: 7846950
    [Abstract] [Full Text] [Related]

  • 14. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial.
    Lee SH, Chen SA, Chiang CE, Tai CT, Wen ZC, Wang SP, Chang MS.
    J Intern Med; 1996 Mar 25; 239(3):253-60. PubMed ID: 8772625
    [Abstract] [Full Text] [Related]

  • 15. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
    Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ.
    Heart; 1998 Jun 25; 79(6):568-75. PubMed ID: 10078083
    [Abstract] [Full Text] [Related]

  • 16. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation.
    Innes GD, Vertesi L, Dillon EC, Metcalfe C.
    Ann Emerg Med; 1997 Jan 20; 29(1):126-34. PubMed ID: 8998091
    [Abstract] [Full Text] [Related]

  • 18. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
    Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE.
    J Am Coll Cardiol; 2000 Sep 20; 36(3):794-802. PubMed ID: 10987602
    [Abstract] [Full Text] [Related]

  • 19. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
    Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI.
    Am J Cardiol; 1991 Aug 01; 68(4):335-41. PubMed ID: 1907089
    [Abstract] [Full Text] [Related]

  • 20. Antiarrhythmic effects of verapamil.
    Singh BN, Nademanee K, Feld G.
    Angiology; 1983 Sep 01; 34(9):572-90. PubMed ID: 6351674
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.